Pfizer jumps into the heated PhIII race for new-wave JAK inhibitors — but safety frets loom large

Submitted by admin on May 15, 2019 - 10:24am

Source:

Endpoints

News Tags:

Pfizer

JAK inhibitors

abrocitinib

anti-inflammatories

Headline:

Pfizer jumps into the heated PhIII race for new-wave JAK inhibitors — but safety frets loom large

snippet:

Pfizer has racked up a positive slate of Phase III data for its anti-inflammatory JAK1 inhibitor abrocitinib (PF-04965842), which the pharma giant is hoping to steer to the FDA relatively soon as it looks to get into a heated blockbuster race that’s been heavily overshadowed by new safety warnings for the class.

Search form

You are here

Pfizer jumps into the heated PhIII race for new-wave JAK inhibitors — but safety frets loom large

Pfizer jumps into the heated PhIII race for new-wave JAK inhibitors — but safety frets loom large